Botulinum toxin has several important properties that make it an ideal chemical denervator. These include its high degree of specificity for the neuromuscular junction, its ability to induce temporary and reversible denervation, and its limited degree of side effects and complications. Botulinum toxin is being used safely in a wide variety of clinical settings by many different specialists. In otolaryngologic practice, it is being administered for the treatment of at least a dozen conditions, including various dysphonias, dystonias, and spasms as well as torticollis, facial nerve paralysis, and hyperkinetic facial lines. Studies have shown that botulinum toxin injections have a high rate of success in temporarily relieving symptoms.
References
1.
SchantzEJ, JohnsonEA. Botulinum toxin: The story of its development for the treatment of human disease. Perspect Biol Med1997;40:317–27.
2.
NIH Consensus Development Panel on Clinical Use of Botulinum Toxin. Botulinum toxin. J Voice1992;6:394–400.
3.
TsuiJK. Botulinum toxin as a therapeutic agent. Pharmacol Ther1996;72:13–24.
4.
SimpsonLL. Clinically relevant aspects of the mechanism of action of botulinum neurotoxin. J Voice1992;6:358–64.
5.
MezakiT, KajiR, KoharaN, Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: A double-blind, controlled study. Neurology1995;45:506–8.
6.
HollandRL, BrownMC. Nerve growth in botulinum toxin poisoned muscles. Neuroscience1981;6:1167–79.
7.
DuchenLW. Changes in the electron microscopic structure of slow and fast skeletal muscle fibres of the mouse after the local injection of botulinum toxin. J Neurol Sci1971;14:61–74.
8.
DuchenLW, StrichSJ. The effects of botulinum toxin on the pattern of innervation of skeletal muscle in the mouse. Q J Exp Physiol Cogn Med Sci1968;53:84–9.
9.
CastellanosPF, GatesGA, EsselmanG, Anatomic considerations in botulinum toxin type A therapy for spasmodic dysphonia. Laryngoscope1994;104:656–62.
10.
WongDL, AdamsSG, IrishJC, Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia. J Otolaryngol1995;24:209–16.
11.
BiglanAW, GonneringR, LockhartLB, Absence of antibody production in patients treated with botulinum A toxin. Am J Ophthalmol1986;101:232–5.
12.
GartlanMG, HoffmanHT. Crystalline preparation of botulinum toxin type A (Botox): Degradation in potency with storage. Otolaryngol Head Neck Surg1993;108:135–40.
13.
SloopRR, ColeBA, EscutinRO. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Neurology1997;48:249–53.
14.
BlitzerA, BrinMF. Laryngeal dystonia: A series with botulinum toxin therapy. Ann Otol Rhinol Laryngol1991;100:85–9.
15.
BlitzerA, BrinMF. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin. J Voice1992;6:365–9.
16.
ZwirnerP, MurryT, SwensonM, WoodsonGE. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: Acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope1992;102:400–6.
17.
WoodsonGE, ZwirnerP, MurryT, SwensonMR. Functional assessment of patients with spasmodic dysphonia. J Voice1992;6:338–43.
18.
FordCN, BlessDM, LoweryJD. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia. Otolaryngol Head Neck Surg1990;103:752–8.
DavidsonBJ, LudlowCL. Long-term effects of botulinum toxin injections in spasmodic dysphonia. Ann Otol Rhinol Laryngol1996;105:33–42.
21.
DeemsDA, SataloffRT. Spasmodic dysphonia. In: SataloffRT. Professional Voice: The Science and Art of Clinical Care. 2nd ed. San Diego: Singular Publishing Group, 1997:499–505.
22.
AdamsSG, HuntEJ, IrishJC, Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. J Otolaryngol1995;24:345–51.
23.
RhewK, FiedlerDA, LudlowCL. Technique for injection of botulinum toxin through the flexible nasolaryngoscope. Otolaryngol Head Neck Surg1994;111:787–94.
24.
GeorgeEF, ZimblerM, WuBL, Quantitative mapping of the effect of botulinum toxin injections in the thyroarytenoid muscle. Ann Otol Rhinol Laryngol1992;101:888–92.
25.
MaloneyAP, MorrisonMD. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia. J Otolaryngol1994;23: 160–4.
26.
LiuTC, IrishJC, AdamsSG, Prospective study of patients’ subjective responses to botulinum toxin injection for spasmodic dysphonia. J Otolaryngol1996;25:66–74.
27.
AdamsSG, HuntEJ, CharlesDA, LangAE. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: Acoustic and perceptual results. J Otolaryngol1993;22:171–5.
28.
Truong [sic; Troung is correct spelling] DD, RontalM, RolnickM, Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope1991;101:630–4.
29.
BrinMF, StewartC, BlitzerA, DiamondB.Laryngeal botulinum toxin injections for disabling stuttering in adults. Neurology1994;44:2262–6.
30.
LudlowCL, NauntonRF, TeradaS, AndersonBJ. Successful treatment of selected cases of abductor spasmodic dysphonia using botulinum toxin injection. Otolaryngol Head Neck Surg1991;104:849–55.
31.
BlitzerA, BrinMF, StewartC, Abductor laryngeal dystonia: A series treated with botulinum toxin. Laryngoscope1992; 102: 163–7.
32.
GrilloneGA, BlitzerA, BrinMF, Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A. Laryngoscope1994; 104:30–2.
33.
MaurielloJAJr., DhillonS, LeoneT, Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. Br J Ophthalmol1996;80: 1073–6.
34.
JordanDR, PatrinelyJR, AndersonRL, ThieseSM. Essential blepharospasm and related dystonias. Surv Ophthalmol1989;34:123–32.
35.
TaylorJD, KraftSP, KazdanMS, Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: A Canadian multicentre study. Can J Ophthalmol1991;26:133–8.
36.
PriceJ, FarishS, TaylorH, O'DayJ.Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections. Ophthalmology1997;104:865–8.
37.
BrinMF, FahnS, MoskowitzC, Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord1987;2:237–54.
38.
JankovicJ, SchwartzK, DonovanDT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry1990;53:633–9.
39.
BiglanAW, MayM, BowersRA. Management of facial spasm with Clostridium botulinum toxin, type A. Arch Otolaryngol Head Neck Surg1988;114:1407–12.
40.
BlitzerA, BrinMF, GreenePE, FahnS.Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol1989;98:93–7.
41.
BorodicGE, JosephM, FayL, Botulinum A toxin for the treatment of spasmodic torticollis: Dysphagia and regional toxin spread. Head Neck1990;12:392–9.
42.
DuttonJJ. Botulinum-A toxin in the treatment of craniocervical muscle spasms: Short- and long-term, local and systemic effects. Surv Ophthalmol1996;41:51–65.
43.
BorodicGE, PearceLB, CheneyM, Botulinum A toxin for treatment of aberrant facial nerve regeneration. Plast Reconstr Surg1993;91:1042–5.
44.
MayM, CroxsonGR, KleinSR. Bell's palsy: Management of sequelae using EMG rehabilitation, botulinum toxin, and surgery. Am J Otol1989;10:220–9.
45.
CarruthersA, KieneK, CarruthersJ.Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol1996;34:788–97.
46.
KeenM, BlitzerA, AvivJ, Botulinumtoxin A for hyperkinetic facial lines: Results of a double-blind, placebo-controlled study. Plast Reconstr Surg1994;94:94–9.
47.
PribitkinEA, GrecoTM, GoodeRL, KeaneWM. Patient selection in the treatment of glabellar wrinkles with botulinum toxin type A injection. Arch Otolaryngol Head Neck Surg1997;123:321–6.
48.
BlitzerA, BrinMF, KeenMS, AvivJE. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg1993;119:1018–22.
49.
LoweNJ, MaxwellA, HarperH.Botulinum A exotoxin for glabellar folds: A double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol1996;35:569–72.
50.
BlitzerA, KomisarA, BaredesS, Voice failure after tracheoesophageal puncture: Management with botulinum toxin. Otolaryngol Head Neck Surg1995;113:668–70.
51.
BlitzerA, BrinMF. Use of botulinum toxin for diagnosis and management of cricopharyngeal achalasia. Otolaryngol Head Neck Surg1997; 116:328–30.
52.
AnneseV, BascianiM, PerriF, Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology1996; 111:1418–24.
